VIA
FULC icon

Virtus Investment Advisers’s Fulcrum Therapeutics FULC Stock Holding History

Virtus Investment Advisers’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$161K Buy
20,974
+511
+2% +$4.74K 0.04% 438
2025
Q4 		$231K Buy
+20,463
New +$208K 0.06% 356

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Virtus Investment Advisers's FULC Position: Q1 2026 in Review

Virtus Investment Advisers increased its Fulcrum Therapeutics (FULC) stake by 2.5% in Q1 2026, buying an estimated $4.74K and bringing the position to 20,974 shares worth $161K. The position accounts for 0.04% of the portfolio, ranked #438.

Virtus Investment Advisers first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. The position peaked at $231K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Virtus Investment Advisers held 20,974 shares of Fulcrum Therapeutics worth $161K as of Q1 2026.
  • Virtus Investment Advisers bought 511 Fulcrum Therapeutics shares in Q1 2026, an estimated $4.74K.
  • Fulcrum Therapeutics made up 0.04% of Virtus Investment Advisers's portfolio in Q1 2026, its #438 holding.
  • Virtus Investment Advisers first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Virtus Investment Advisers's Fulcrum Therapeutics position peaked at $231K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.